NO2020033I1 - andeksanet alfa - Google Patents

andeksanet alfa

Info

Publication number
NO2020033I1
NO2020033I1 NO2020033C NO2020033C NO2020033I1 NO 2020033 I1 NO2020033 I1 NO 2020033I1 NO 2020033 C NO2020033 C NO 2020033C NO 2020033 C NO2020033 C NO 2020033C NO 2020033 I1 NO2020033 I1 NO 2020033I1
Authority
NO
Norway
Prior art keywords
andexane
alpha
andexane alpha
Prior art date
Application number
NO2020033C
Other languages
English (en)
Original Assignee
Portola Pharm Inc
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc, Alexion Pharma Inc filed Critical Portola Pharm Inc
Publication of NO2020033I1 publication Critical patent/NO2020033I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
NO2020033C 2007-09-28 2020-09-23 andeksanet alfa NO2020033I1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97634307P 2007-09-28 2007-09-28
US9057408P 2008-08-20 2008-08-20
PCT/US2008/078014 WO2009042962A2 (en) 2007-09-28 2008-09-26 Antidotes for factor xa inhibitors and methods of using the same
EP08834136.7A EP2193196B1 (en) 2007-09-28 2008-09-26 Antidotes for factor xa inhibitors and methods of using the same

Publications (1)

Publication Number Publication Date
NO2020033I1 true NO2020033I1 (no) 2020-09-23

Family

ID=40481812

Family Applications (2)

Application Number Title Priority Date Filing Date
NO2019040C NO2019040I1 (no) 2007-09-28 2019-11-08 andeksanet alfa
NO2020033C NO2020033I1 (no) 2007-09-28 2020-09-23 andeksanet alfa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO2019040C NO2019040I1 (no) 2007-09-28 2019-11-08 andeksanet alfa

Country Status (27)

Country Link
US (8) US8153590B2 (no)
EP (4) EP2193196B1 (no)
JP (6) JP5637561B2 (no)
KR (4) KR20170100071A (no)
CN (4) CN103446579B (no)
AU (6) AU2008304192B9 (no)
BR (2) BRPI0816837B1 (no)
CA (1) CA2697583C (no)
CY (3) CY1118482T1 (no)
DK (3) DK2915564T3 (no)
ES (3) ES2849426T3 (no)
FR (1) FR20C1045I2 (no)
HK (1) HK1210443A1 (no)
HR (2) HRP20161255T1 (no)
HU (4) HUE050063T2 (no)
IL (4) IL203993A (no)
LT (3) LT3078743T (no)
MX (1) MX2010003095A (no)
NL (1) NL301063I2 (no)
NO (2) NO2019040I1 (no)
NZ (1) NZ583944A (no)
PL (3) PL2193196T3 (no)
PT (3) PT3078743T (no)
SG (1) SG185263A1 (no)
SI (3) SI2193196T1 (no)
WO (1) WO2009042962A2 (no)
ZA (2) ZA201002039B (no)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696352B2 (en) * 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
MX2008014193A (es) 2006-05-05 2009-03-31 Millennium Pharm Inc Inhibidores del factor xa.
KR20170100071A (ko) 2007-09-28 2017-09-01 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
US8268783B2 (en) 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
MX2011004907A (es) 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
DK2379096T3 (da) 2008-12-19 2019-11-25 Baxalta GmbH TFPI-inhibitorer og fremgangsmåder til anvendelse
ES2605801T3 (es) * 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
ES2620421T3 (es) * 2009-10-30 2017-06-28 Senova Gesellschaft für Biowissenschaft und Technik mbH Peptidasas acopladas a polímero
US8530501B2 (en) 2009-12-17 2013-09-10 Millennium Pharmaceuticals, Inc. Salts and crystalline forms of a factor Xa inhibitor
WO2011075602A1 (en) 2009-12-17 2011-06-23 Millennium Pharmaceuticals, Inc. Methods of preparing factor xa inhibitors and salts thereof
TWI513466B (zh) * 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
JP5730983B2 (ja) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
AR082804A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Formas cristalinas de un inhibidor del factor xa
AR082803A1 (es) * 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
CN103619883A (zh) * 2011-01-19 2014-03-05 拜耳知识产权有限责任公司 凝血因子抑制剂的结合蛋白
FR2972114B1 (fr) * 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
EP2691156A1 (en) 2011-03-30 2014-02-05 Boehringer Ingelheim International GmbH Anticoagulant antidotes
WO2013049804A1 (en) * 2011-09-30 2013-04-04 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
PL2785700T3 (pl) * 2011-11-29 2016-09-30 Środki odwracające działanie przeciwzakrzepowe
EP2814955A1 (en) 2012-02-14 2014-12-24 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
EP2814503A1 (en) * 2012-02-16 2014-12-24 Portola Pharmaceuticals, Inc. MODULATION OF FACTOR Xa INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE
CN109111505A (zh) 2012-03-21 2019-01-01 百深有限责任公司 Tfpi抑制剂及其使用方法
KR102100629B1 (ko) * 2012-06-14 2020-04-16 포톨라 파마슈티컬스, 인코포레이티드 재조합 인자 Xa 유도체의 정제방법
JP6363600B2 (ja) 2012-07-25 2018-07-25 カタリスト・バイオサイエンシーズ・インコーポレイテッドＣａｔａｌｙｓｔ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 修飾第ｘ因子ポリペプチドおよびその使用
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
FR3000895B1 (fr) * 2013-01-11 2017-02-24 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques
US20150352194A1 (en) * 2013-01-24 2015-12-10 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
MX2015008813A (es) 2013-01-31 2016-03-31 Pfizer Composiciones y metodos para contrarrestar la inhibicion del factor xa.
FR3007410B1 (fr) * 2013-06-21 2016-05-27 Lab Francais Du Fractionnement Facteur x depourvu de domaine gla
CA2924981C (en) 2013-09-24 2020-03-31 Pfizer, Inc. Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
US20160235824A1 (en) * 2013-11-01 2016-08-18 The Children's Hospital Philadelphia Compositions and Methods for Increasing the Half-Life of Factor XA
SG11201609811TA (en) 2014-05-26 2016-12-29 Academisch Ziekenhuis Leiden Prohemostatic proteins for the treatment of bleeding
ES2907190T3 (es) * 2014-07-31 2022-04-22 Haemonetics Corp Detección de la reversión de un anticoagulante mediante pruebas de coagulación por ecarina y factor Xa
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
EA202091385A3 (ru) * 2014-08-20 2021-06-30 Портола Фармасьютикалз, Инк. Лиофилизированные составы для антидота фактора ха
CN105030703B (zh) * 2015-06-23 2018-03-23 上海旭东海普药业有限公司 一种防治疗栓塞性疾病的利伐沙班片及其制备方法
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
US20190046450A1 (en) 2016-02-24 2019-02-14 Portola Pharmaceuticals, Inc. Lyophilized formulations for factor xa antidote
US10438662B2 (en) 2016-02-29 2019-10-08 Iridia, Inc. Methods, compositions, and devices for information storage
US10640822B2 (en) 2016-02-29 2020-05-05 Iridia, Inc. Systems and methods for writing, reading, and controlling data stored in a polymer
US10859562B2 (en) 2016-02-29 2020-12-08 Iridia, Inc. Methods, compositions, and devices for information storage
AU2017227608B2 (en) * 2016-02-29 2023-06-01 Iridia, Inc. Methods, compositions, and devices for information storage
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EA037815B1 (ru) * 2016-06-17 2021-05-25 Портола Фармасьютикалз, Инк. ПОЛУЧЕНИЕ ПРОИЗВОДНЫХ ФАКТОРА Xa
WO2018115235A1 (en) 2016-12-22 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antidotes to anti-coagulant drugs allowing diagnosis and treatment
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CN111246821A (zh) * 2017-08-21 2020-06-05 美国绿阳生物技术及医药公司 光吸收组合物和使用方法
CN118745229A (zh) 2017-11-15 2024-10-08 诺和诺德股份有限公司 增强fx活化的因子x结合物
JP2021527435A (ja) * 2018-06-19 2021-10-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤に対する解毒剤
BR112021002675A2 (pt) * 2018-08-14 2021-05-11 Jiangsu Hengrui Medicine Co., Ltd. composições farmacêuticas, métodos para preparar as referidas composições e uso das mesmas
US11655465B1 (en) 2019-05-02 2023-05-23 Iridia, Inc. Enzymes and systems for synthesizing DNA
US20220251534A1 (en) 2019-08-08 2022-08-11 Alexion Pharmaceuticals, Inc. Compositions and methods for preparing factor xa and derivatives
US11837302B1 (en) 2020-08-07 2023-12-05 Iridia, Inc. Systems and methods for writing and reading data stored in a polymer using nano-channels
EP3971576A1 (en) 2020-09-21 2022-03-23 Instrumentation Laboratory Company Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample
CN113484386B (zh) * 2021-05-21 2024-02-13 郑州轻工业大学 一种金属聚酞菁纳米材料的制备方法及其应用，适配体传感器及其制备方法
CN114681597A (zh) * 2022-03-11 2022-07-01 兆科药业（合肥）有限公司 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用
CN116327627B (zh) * 2023-03-10 2024-06-07 四川大学 一种四面体框架核酸-光甘草定复合物及其在皮肤美白方面的用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH596313A5 (no) * 1975-05-30 1978-03-15 Battelle Memorial Institute
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
AU4434585A (en) 1985-03-30 1986-10-23 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4818700A (en) 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4812405A (en) 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5597799A (en) * 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5278144A (en) * 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
CA2103577A1 (en) 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DK0608261T3 (da) 1991-09-13 2003-03-17 Chiron Corp Sammensætninger med immunreaktivt hepatitis C virus polypeptid
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
JPH07507769A (ja) 1992-03-20 1995-08-31 コアー・セラピュティックス・インコーポレーテッド Ｘ因子のグリコシル化媒介による阻害
DE69434486T2 (de) 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
WO1995011984A2 (en) 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
SE9604744D0 (sv) 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A modified coagulation agent
AT405517B (de) * 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AU6673898A (en) * 1997-03-07 1998-09-22 Washington University Factor x variant
JPH1149800A (ja) 1997-06-05 1999-02-23 Fujimori Kogyo Kk アンヒドロトロンビンの合成方法
DE69942021D1 (de) 1998-04-20 2010-04-01 Glycart Biotechnology Ag Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
DE69938054T2 (de) 1998-11-18 2009-02-12 Genentech, Inc., South San Francisco Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US6258559B1 (en) 1999-03-22 2001-07-10 Zymogenetics, Inc. Method for producing proteins in transformed Pichia
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6858599B2 (en) 1999-06-30 2005-02-22 Mochida Pharmaceutical Co., Ltd. Tricyclic compound having spiro union
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
ATE311366T1 (de) 2000-02-29 2005-12-15 Millennium Pharm Inc Benzamide und ähnliche inhibitoren vom faktor xa
WO2001068605A1 (en) 2000-03-13 2001-09-20 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
WO2002020569A2 (en) 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
US7070740B1 (en) 2000-09-28 2006-07-04 Beckman Coulter, Inc. Method and apparatus for processing biomolecule arrays
US20030064414A1 (en) 2001-03-30 2003-04-03 Benecky Michael J. Rapid assessment of coagulation activity in whole blood
WO2002090599A1 (en) 2001-05-09 2002-11-14 Genetic Id, Inc. Universal microarray system
US6989267B2 (en) 2001-07-02 2006-01-24 Agilent Technologies, Inc. Methods of making microarrays with substrate surfaces having covalently bound polyelectrolyte films
DE10155075A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Cyclische Sulfonamide
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CN1480466A (zh) * 2002-09-03 2004-03-10 �й������ž�����ҽѧ��ѧԺ����ҽ 一类溶栓抗凝双功能融合蛋白及应用
US20040198660A1 (en) 2002-11-06 2004-10-07 Petersen Lars Christian Tissue factor antagonist and protein C polypeptide compositions
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
EP1723422A2 (en) 2004-03-05 2006-11-22 The Scripps Research Institute High throughput glycan microarrays
JP4441336B2 (ja) 2004-06-11 2010-03-31 日本碍子株式会社 マイクロアレイの製造方法
US9223929B2 (en) 2005-03-14 2015-12-29 The California Institute Of Technology Method and apparatus for detection, identification and quantification of single-and multi-analytes in affinity-based sensor arrays
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
WO2006102687A1 (en) 2005-03-22 2006-09-28 The Trustees Of Columbia University In The City Of New York A liposome-based microarray and methods of use thereof
BRPI0618362A2 (pt) 2005-11-08 2011-08-30 Millennium Pharm Inc sais farmacêuticos inovadores e polimorfos de um inibidor de fator xa
US20070111322A1 (en) 2005-11-15 2007-05-17 Lin-Cheng Yang Novel method of using inject printing for creating microarrays
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
US8268783B2 (en) * 2007-09-28 2012-09-18 Portola Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same
KR20170100071A (ko) * 2007-09-28 2017-09-01 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
MX2011004907A (es) * 2008-11-14 2011-07-29 Portola Pharm Inc Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre.
WO2010070137A1 (en) 2008-12-19 2010-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders
ES2605801T3 (es) * 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia

Also Published As

Publication number Publication date
CY1118482T1 (el) 2017-07-12
WO2009042962A9 (en) 2009-09-11
FR20C1045I1 (no) 2020-10-30
US20200276280A1 (en) 2020-09-03
KR102069498B1 (ko) 2020-01-23
CY1123504T1 (el) 2021-06-25
HRP20161255T1 (hr) 2016-12-02
EP3824902A1 (en) 2021-05-26
EP3078743B1 (en) 2020-06-24
CY2020042I2 (el) 2021-06-25
ES2849426T3 (es) 2021-08-18
JP5637561B2 (ja) 2014-12-10
US20140079684A1 (en) 2014-03-20
BR122022001846B1 (pt) 2022-12-27
DK2193196T3 (en) 2016-11-07
SI3078743T1 (sl) 2020-08-31
AU2008304192B2 (en) 2014-05-15
CA2697583A1 (en) 2009-04-02
PL3078743T3 (pl) 2020-11-02
AU2014210620B2 (en) 2016-05-12
IL255397A0 (en) 2017-12-31
BRPI0816837B1 (pt) 2022-10-18
AU2014210620A1 (en) 2014-08-28
US10675335B2 (en) 2020-06-09
IL203993A0 (en) 2011-07-31
IL255397B (en) 2019-03-31
US8889129B2 (en) 2014-11-18
LT2193196T (lt) 2016-12-12
AU2008304192B9 (en) 2024-02-01
US20120269788A1 (en) 2012-10-25
US11839646B2 (en) 2023-12-12
HK1210443A1 (en) 2016-04-22
CN102533702A (zh) 2012-07-04
PL2193196T3 (pl) 2017-07-31
WO2009042962A2 (en) 2009-04-02
HUE031647T2 (en) 2017-07-28
ZA201406514B (en) 2016-10-26
US20090098119A1 (en) 2009-04-16
WO2009042962A3 (en) 2009-06-04
CY2020042I1 (el) 2021-06-25
CN103446579A (zh) 2013-12-18
US20150057228A1 (en) 2015-02-26
US8455441B2 (en) 2013-06-04
SI2915564T1 (sl) 2021-03-31
HUE050063T2 (hu) 2020-11-30
AU2019204123A1 (en) 2019-07-04
CA2697583C (en) 2016-04-12
KR102271404B1 (ko) 2021-07-02
FR20C1045I2 (fr) 2021-08-27
ES2796623T3 (es) 2020-11-27
US9062298B2 (en) 2015-06-23
PT2915564T (pt) 2021-02-09
IL203993A (en) 2017-11-30
EP2193196A2 (en) 2010-06-09
KR20160025038A (ko) 2016-03-07
JP2017043632A (ja) 2017-03-02
JP2018100290A (ja) 2018-06-28
EP3078743A1 (en) 2016-10-12
PT3078743T (pt) 2020-07-15
EP2915564A1 (en) 2015-09-09
HRP20201071T1 (hr) 2020-10-30
BRPI0816837A2 (pt) 2020-08-18
ZA201002039B (en) 2015-11-25
DK3078743T3 (da) 2020-08-10
CN102559644B (zh) 2015-03-25
SG185263A1 (en) 2012-11-29
KR20170100071A (ko) 2017-09-01
NO2019040I1 (no) 2019-11-08
JP2010539945A (ja) 2010-12-24
IL272926A (en) 2020-04-30
AU2021218033A1 (en) 2021-09-09
AU2017200212A1 (en) 2017-02-02
ES2597436T3 (es) 2017-01-18
KR20200009131A (ko) 2020-01-29
LTPA2020540I1 (lt) 2021-01-11
JP2022153574A (ja) 2022-10-12
US8153590B2 (en) 2012-04-10
JP2020109113A (ja) 2020-07-16
US9388401B2 (en) 2016-07-12
PL2915564T3 (pl) 2021-07-19
PT2193196T (pt) 2016-10-24
KR101698214B1 (ko) 2017-01-20
NL301063I2 (nl) 2021-06-23
EP2915564B1 (en) 2020-11-04
HUS2000057I1 (hu) 2021-01-28
LTC3078743I2 (lt) 2022-06-10
US20160354449A1 (en) 2016-12-08
EP2193196B1 (en) 2016-07-13
US20240082367A1 (en) 2024-03-14
AU2008304192A2 (en) 2010-04-08
CN101802188B (zh) 2013-08-21
NL301063I1 (no) 2020-09-16
DK2915564T3 (da) 2021-02-08
AU2013205326A8 (en) 2013-06-06
NZ583944A (en) 2012-06-29
HUE052423T2 (hu) 2021-04-28
JP2014218521A (ja) 2014-11-20
LT3078743T (lt) 2020-09-25
SI2193196T1 (sl) 2017-01-31
AU2008304192A1 (en) 2009-04-02
AU2013205326A1 (en) 2013-05-09
JP6300885B2 (ja) 2018-03-28
CN102559644A (zh) 2012-07-11
CN101802188A (zh) 2010-08-11
US20140044773A1 (en) 2014-02-13
MX2010003095A (es) 2010-04-09
KR20100077172A (ko) 2010-07-07
IL264886B (en) 2020-03-31
JP6047127B2 (ja) 2016-12-21
CN103446579B (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
NO2020033I1 (no) andeksanet alfa
NL301210I1 (nl) Avalglucosidase alfa
NL301211I2 (nl) Olipudase alfa
NO2019047I1 (no) ravulizumab
NL300828I2 (nl) albutrepenonacog alfa
ATE501136T1 (de) Imidazopyridinone
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE112008003636A5 (de) Mehrzuggruppierer
DE502007001207D1 (de) Elektrosaugkopf
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0812840A2 (pt) 2-imidazolinas
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
AT505058A3 (de) Türschliesssystem
BRPI0812994A2 (pt) Microbiocidas
DK2155273T3 (da) Lugtregulerende genstand
DE112008001216A5 (de) Magnetronplasmaanlage
DE502008001694D1 (de) Mitfahrhubwagen
DE112008003094A5 (de) Geomatte
DE502008003063D1 (de) Magnetventilinjektor
DE112008003196A5 (de) Handpipettiergerät
DE112008002200A5 (de) Sperrsynchronisiervorrichtung
CU20090155A7 (es) Macrolidos
DE102007038931A8 (de) Fadenlagennähwirkstoffe
DE112008002909A5 (de) Verwahrbehältnis